GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
CAMBRIDGE, Mass., March 03, 2016 -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today announced that Thomas Mathers, Chief Executive Officer, will present a corporate overview at the Cowen &Company 36th Annual Health Care Conference, taking place March 7-9 at the Boston Marriott Copley Place.
| Cowen & Company 36th Annual Health Care Conference -- CoLucid Presentation Details | |
| Date: | Tuesday, March 8 |
| Time: | 8:40am – 9:10am Eastern Time |
| Location: | Boston Marriott Copley Place, Berkeley Room, 3rd Floor |
| Webcast: | http://wsw.com/webcast/cowen30/clcd |
About CoLucid Pharmaceuticals, Inc.
CoLucid is developing oral lasmiditan for the acute treatment of migraine in adults and intravenous lasmiditan for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings.
CONTACT Thomas Mathers Chief Executive Officer CoLucid Pharmaceuticals, Inc. (781) 365-2596 Hans Vitzthum Managing Director LifeSci Advisors, LLC. (212) 915-2568
